<DOC>
	<DOCNO>NCT00045227</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining vaccine therapy chemotherapy may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness vaccine therapy without docetaxel treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Vaccine Therapy With Without Docetaxel Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare relative change prostate-specific antigen ( PSA ) -specific T-cell precursor ( CD8 ) baseline day 85 patient metastatic androgen-independent prostate cancer treat vaccination regimen comprise fowlpox-PSA vaccine , recombinant rV-B7.1 vaccine , recombinant vaccinia-PSA vaccine , sargramostim ( GM-CSF ) without docetaxel . - Compare safety regimens patient . - Compare clinical activity regimens patient . - Determine immunologic effect patient additional vaccine/chemotherapy course . - Measure CD4 T-cell response vaccine patient . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm receive prim vaccination . - Priming vaccination : All patient receive recombinant vaccinia-prostate-specific antigen ( PSA ) vaccine subcutaneously ( SC ) recombinant rV-B7.1 vaccine SC day 1 sargramostim ( GM-CSF ) SC day 1-4 . Patients receive fowlpox-PSA vaccine ( F-PSA ) SC day 15 GM-CSF SC day 15-18 . - Arm I : Patients receive docetaxel IV 30 minute day 29 , 36 , 43 ; F-PSA SC day 30 ; GM-CSF SC day 30-33 . Treatment repeat begin day 56 one course . Patients disease progression day 85 receive docetaxel weekly 3 week F-PSA day 1 course . Courses repeat every 4 week absence disease progression unacceptable toxicity . - Arm II : Patients receive F-PSA SC day 29 57 GM-CSF SC day 29-32 57-60 . Patients show disease progression day 85 either radiographically rise PSA stop receiving vaccine may receive docetaxel weekly 3 week . Chemotherapy repeat every 4 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 28 patient ( 14 per treatment arm ) accrue study within 9-10 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis androgenindependent metastatic adenocarcinoma prostate , confirm 1 following : Histologically confirm disease Pathologically document disease clinical course consistent prostate cancer Castrate level testosterone progressive disease least 1 follow parameter : 2 consecutively rise prostatespecific antigen level , separate least 1 week , least 1 measurement 50 % nadir reach last therapeutic maneuver ( must least 5 ng/mL ) At least 1 new metastatic deposit technetium Tc 99 bone scintigraphy Progression softtissue metastasis image palpation , indicate : Development new area malignant disease At least 20 % increase sum long dimension target lesion Serum testosterone less 50 ng/dL prior surgical castration Luteinizing hormonereleasing hormone therapy must continue HLAA2 positive No brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 6 month Hematopoietic Granulocyte count least 1,500/mm^3 Lymphocyte count least 500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin le 1.5 mg/dL AST ALT less 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN OR Hepatic alkaline phosphatase fraction le 2.5 time ULN Renal Creatinine great 1.5 mg/dL OR Creatinine clearance least 40 mL/min Proteinuria grade 01 OR Protein le 1,000 mg 24hour urine collection No hematuria No abnormal sediment unless nonrenal Cardiovascular No unstable newly diagnose angina pectoris No myocardial infarction within past 6 month No New York Heart Association class IIIV congestive heart failure No concurrent clinically significant cardiomyopathy require treatment Immunologic No prior allergy untoward reaction vaccinia virus vaccination No alter immune function , include : Eczema Atopic dermatitis HIV Autoimmune disease Autoimmune neutropenia Thrombocytopenia Hemolytic anemia Systemic lupus erythematosus Sjogren 's syndrome Scleroderma Myasthenia gravis Goodpasture syndrome Addison 's disease Hashimoto 's thyroiditis Active Graves ' disease Multiple sclerosis No extensive psoriasis , severe acneiform rash , impetigo , varicella zoster , burn , traumatic pruritic skin condition No known allergy egg Other No malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ bladder No lifethreatening serious illness No unhealed surgical scar No household close physical contact person follow condition 2 week study treatment : Eczema eczematoid skin disorder Acute , chronic , exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) Pregnant nurse woman Children 5 year age Immunodeficient immunosuppressed ( include HIV positive ) individual No history seizures encephalitis PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior taxanes metastatic prostate cancer Endocrine therapy See Disease Characteristics At least 4 week since prior flutamide At least 6 week since prior bicalutamide nilutamide No concurrent steroid except topical steroid , inhaled steroid mild moderate asthma , decadron premedication chemotherapy Radiotherapy Not specify Surgery See Disease Characteristics No prior splenectomy Other Recovered prior therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>